A team of basic and clinical scientists led by the University of Montreal Hospital* Research Centre’s (CRCHUM) Dr. Nathalie Arbour has opened the door to significantly improved treatments for the symptoms of Multiple Sclerosis (MS). In a study selected as among the top 10% most interesting articles published in the Journal of Immunology, the team identifies the elevated presence in MS patients of a type of white blood cell (CD4 T cell) that expresses NKG2C, a highly-toxic molecule harmful to brain tissues.
In close collaboration with clinicians at the University of Montreal Hospital and the Montreal Neurological Institute, McGill University, Dr. Arbour’s team studied tissues from healthy subjects and MS patients. This approach enabled the team to uncover a novel mechanism by which CD4 T cells expressing NKG2C can directly target brain cells having a specific corresponding ligand found only in MS patients. “These results are very encouraging,” says Arbour, “since they provide us with a much more refined picture of how the brain cells of MS patients are targeted by the immune system and provide us with a clearer understanding of how to go about blocking their action.”
There is no known cure for this auto-immune disease of the central nervous system. While there are a number of approved MS therapies targeting molecules expressed by immune cells, they are sometimes too broad in their application. They can suppress the efficiency of the immune system but also open the way for serious infections in some MS patients such as progressive multifocal leukoencephalopathy, a serious viral disease that can cause death in people with severe immune deficiency, such as MS patients on immunosuppressive medication.
“Our research has made an important step in getting around this problem. Because NKG2C is specifically expressed by a subset of CD4 T cells only found in MS patients, targeting this receptor would not affect large populations of immune cells, but only those which produce the symptoms characteristic of this debilitating disease,” explains Arbour.
For patients this discovery could translate into improved treatments aimed at decreasing the progression of the disease and its symptoms, without the risk of potentially lethal infections and therefore improving their quality of life.
About Multiple Sclerosis
With more than 75,000 Multiple Sclerosis patients, Canada has one of the highest incidences of the disease in the world. The intrusion of the body’s immune system into the brain affects the ability of neurons in the brain and in the spinal cord to communicate efficiently with one another, producing extensive and recurrent central nervous system damage. Multiple Sclerosis symptoms can include paralysis, pricking or numbness, visual problems, difficulties with coordination, balance and movement, which lead to chronic handicap.
About the study
“Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis” was featured in the March 15 issue of the Journal of Immunology, where it was selected as being among the top 10% most interesting articles published in the journal. The research team included basic and clinical scientists from the University of Montreal Hospital and the Montreal Neurological Institute, McGill University.
About Dr. Nathalie Arbour
Dr. Arbour is a researcher in the Neuroscience Axis at the University of Montreal Hospital Research Centre and a Research Associate Professor at the Department of Medicine, University of Montreal. Her research program is funded by the Multiple Sclerosis Society of Canada, the Canada Foundation for Innovation and she currently holds a New Investigator Award from the Canadian Institutes of Health Research.
About the CRCHUM
The University of Montreal Hospital* Research Centre (CRCHUM) improves the health of adults through a high-quality academic research continuum which, by improving our understanding of etiological and pathogenic mechanisms, fosters the development, implementation and assessment of new preventive, diagnostic and therapeutic strategies. The CRCHUM provides a training environment to ensure the development of new generations of researchers committed to research excellence. *The University of Montreal Hospital and the University of Montreal are known officially as Centre hospitalier de l’Université de Montréal and Université de Montréal, respectively.
Source of text and image: Communication Division, Centre hospitalier de l’Université de Montréal (CHUM) http://www.chumtl.qc.ca/crchum/crchum-news/communique19032013.en.html
Original Research Article Reference:
Zaguia F, Saikali P, Ludwin S, Newcombe J, Beauseigle D, McCrea E, Duquette P,
Prat A, Antel JP, Arbour N. Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes
in Multiple Sclerosis. J Immunol. 2013 Mar 15;190(6):2510-8. PubMed
